Also, miR-17 forms FBL with the activator E2Fs (E2F1 and E2F3), in which the activating effects of E2F1 and E2F3 probably overcome the inhibitory effect of miR-17 during the PD progression. This evidence concerns the gene E2F1 and Parkinson disease.